Chronic kidney disease in the BCR-ABL1-negative myeloproliferative neoplasm: a single-center retrospective study
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Renal complications related to BCR-ABL1-negative myeloproliferative neoplasms (MPNs) have not been examined fully in Asian populations. Methods: We analyzed estimated glomerular filtration rate (eGFR) and its changes with time retrospectively in patients with BCR-ABL1-negative MPN from 2005 to 2015. Results: The prevalence of chronic kidney disease (CKD) was 11% (6.6% having stage 3 and 4.4% having stage 4). In a linear regression analysis of eGFR versus time (years), overall, patients showed increased eGFR (mL/min/1.73 m2) by 0.51 (95% confidence interval [CI], –0.30 to 1.33; p = 0.22). Patients with polycythemia vera (PV), and those treated with hydroxyurea, showed statistically significant increases in eGFR (1.59; 95% CI, 0.28 to 2.90; p = 0.02 in PV; and 1.55; 95% CI, 0.56 to 2.54; p = 0.02 in treatment with hydroxyurea). In total, 17 patients (20.5%) showed rapid loss of eGFR (< –3 mL/min/1.73 m2 per year). This rapid loss in eGFR was associated with a higher incidence of kidney disease (23.5% vs. 6.1%, p = 0.05) and a higher percentage of patients with high neutrophil (> 7.0 × 109/L) and high monocyte (> 0.7 × 109/L) counts (76.5% vs. 50%, p = 0.05; 52.9% vs. 28.8%, p = 0.06, respectively). More patients had high serum lactate dehydrogenase (> 500 U/L) levels (52.9% vs. 25.8%, p = 0.03) at diagnosis. Conclusions: CKD is prevalent in patients with BCR-ABL1-negative MPN. Active cytoreductive therapy has the potential to improve kidney function in BCR-ABL1-negative MPN.
Abstract
Background/Aims: Renal complications related to BCR-ABL1-negative myeloproliferative neoplasms (MPNs) have not been examined fully in Asian populations. Methods: We analyzed estimated glomerular filtration rate (eGFR) and its changes with time retrospectively in patients with BCR-ABL1-negative MPN from 2005 to 2015. Results: The prevalence of chronic kidney disease (CKD) was 11% (6.6% having stage 3 and 4.4% having stage 4). In a linear regression analysis of eGFR versus time (years), overall, patients showed increased eGFR (mL/min/1.73 m2) by 0.51 (95% confidence interval [CI], –0.30 to 1.33; p = 0.22). Patients with polycythemia vera (PV), and those treated with hydroxyurea, showed statistically significant increases in eGFR (1.59; 95% CI, 0.28 to 2.90; p = 0.02 in PV; and 1.55; 95% CI, 0.56 to 2.54; p = 0.02 in treatment with hydroxyurea). In total, 17 patients (20.5%) showed rapid loss of eGFR (< –3 mL/min/1.73 m2 per year). This rapid loss in eGFR was associated with a higher incidence of kidney disease (23.5% vs. 6.1%, p = 0.05) and a higher percentage of patients with high neutrophil (> 7.0 × 109/L) and high monocyte (> 0.7 × 109/L) counts (76.5% vs. 50%, p = 0.05; 52.9% vs. 28.8%, p = 0.06, respectively). More patients had high serum lactate dehydrogenase (> 500 U/L) levels (52.9% vs. 25.8%, p = 0.03) at diagnosis. Conclusions: CKD is prevalent in patients with BCR-ABL1-negative MPN. Active cytoreductive therapy has the potential to improve kidney function in BCR-ABL1-negative MPN.
참고문헌 (25)
- Vardiman JW, "The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes", Blood, 114, pp.937~951 (2009)[DOI]
- Tefferi A, "Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1", Leukemia, 24, pp.1128~1138 (2010)[DOI]
- Tefferi A, "An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms", Leukemia, 28, pp.1407~1413 (2014)[DOI]
- Elliott MA, "Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia", Br J Haematol, 128, pp.275~290 (2005)[DOI]
- Oymak O, "Polycythemia vera presenting with rapidly progressive glomerulonephritis and pyoderma gangrenosum", Nephron, 86, pp.346~347 (2000)[DOI]
- Plomley RF, "Polycythemia vera and glomerulonephritis", Aust N Z J Med, 13, pp.125~129 (1983)[DOI]
- Asaba K, "Fibrillary glomerulonephritis associated with essential thrombocytosis", Clin Exp Nephrol, 7, pp.296~300 (2003)[DOI]
- Kornblihtt LI, "Primary myelofibrosis in a patient who developed primary biliary cirrhosis, autoimmune hemolytic anemia and fibrillary glomerulonephritis", Ann Hematol, 87, pp.1019~1020 (2008)[DOI]
- 정영종, "진성다혈구증에 병발한 미세변화신증을 동반한 IgA 신병증 1예", Kidney Research and Clinical Practice, 27(6), pp.733~737 (2008), 대한신장학회
- 한대희, "진성다혈구증에 병발된 미세변화형 신증 1예", 대한내과학회지, 73(4), pp.438~442 (2007), 대한내과학회
- 박명옥, "진성적혈구증다증에 동반된 국소성분절성사구체경화증 1예", Blood Research, 42(1), pp.8~8 (2007), 대한혈액학회
- Said SM, "Myeloproliferative neoplasms cause glomerulopathy", Kidney Int, 80, pp.753~759 (2011)[DOI]
- Christensen AS, "Chronic kidney disease in patients with the Philadelphia-negative chronic myeloproliferative neoplasms", Leuk Res, 38, pp.490~495 (2014)[DOI]
- Kleihues P, "World Health Organization classification of tumors", Cancer, 88, pp.2887~ (2000)[DOI]
- Jones GR, "The National Kidney Foundation guideline on estimation of the glomerular filtration rate", Clin Biochem Rev, 24, pp.95~98 (2003)
- Levey AS, "National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification", Ann Intern Med, 139, pp.137~147 (2003)[DOI]
- Lee HM, "Prevalence of chronic kidney disease in Korea, 2013", Public Health Wkly Rep, 8, pp.242~244 (2013)
- Totani L, "Platelet-leukocyte interactions in cardiovascular disease and beyond", Arterioscler Thromb Vasc Biol, 30, pp.2357~2361 (2010)[DOI]
- Kanbay M, "Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions", Int Urol Nephrol, 39, pp.1227~1233 (2007)[DOI]
- Khosla UM, "Hyperuricemia induces endothelial dysfunction", Kidney Int, 67, pp.1739~1742 (2005)[DOI]
- Sanchez-Lozada LG, "Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats", Kidney Int, 67, pp.237~247 (2005)[DOI]
- Skov V, "Molecular profiling of peripheral blood cells from patients with polycythemia vera and related neoplasms: identification of deregulated genes of significance for inflammation and immune surveillance", Leuk Res, 36, pp.1387~1392 (2012)[DOI]
- Martyre MC, "TGF-beta and megakaryocytes in the pathogenesis of myelofibrosis in myeloproliferative disorders", Leuk Lymphoma, 20, pp.39~44 (1995)[DOI]
- Martyre MC, "Increased intraplatelet levels of platelet-derived growth factor and transforming growth factor-beta in patients with myelofibrosis with myeloid metaplasia", Br J Haematol, 77, pp.80~86 (1991)[DOI]
- Levey AS, "K", DOQI clinical practice guidelines for chronic kidney disease, 2002, pp.39(2 suppl 1), S11~S12